Trial Profile
Canakinumab in patients with Schnitzler's syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2013
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Schnitzler syndrome
- Focus Therapeutic Use
- 17 Dec 2013 New trial record
- 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.